Supported in part by AstraZeneca and Daiichi Sankyo, content independently developed by OncLive.
Charles E. Geyer, MD, discusses data from the DESTINY-Breast05 safety analysis evaluating ILD and radiation pneumonitis outcomes in HER2+ breast cancer.
Charles E. Geyer, MD, discusses ILD and radiation pneumonitis incidence by radiotherapy timing with T-DXd in a DESTINY-Breast05 safety analysis.
Javier Cortés, MD, PhD, discusses additional TROPION-Breast02 end points supporting the first-line use of Dato-DXd in metastatic TNBC.
Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.
Sara M. Tolaney, MD, MPH, discusses research inspired by an analysis of first-line T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, PhD, notes the emergence of TROP2-directed ADCs in first-line TNBC management and the sequencing questions their arrival raises.
Sara A. Hurvitz, MD, FACP, discusses updated data with a switch to camizestrant upon detecting a ctDNA-emergent ESR1 mutation in metastatic breast cancer.
Paolo Tarantino, MD, PhD, notes the implications of updated safety data with post-neoadjuvant T-DXd in high-risk, HER2-positive early breast cancer.
Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.
Mabel Mardones, MD, discusses data for first-line giredestrant plus palbociclib in ER-positive, HER2-negative advanced breast cancer.
Sara M. Tolaney, MD, MPH, discusses an analysis of depth of response in HER2-positive advanced/metastatic breast cancer treated with T-DXd plus pertuzumab.
Patients with metastatic breast cancer achieving a CR/deep PR with frontline T-DXd/pertuzumab had the most durable PFS outcomes in DESTINY-Breast09.
Dato-DXd led to benefits in terms of TFST, PFS2, and TSST vs chemotherapy in frontline TNBC.
A switch to camizestrant upon emergence of an ESR1 mutation improved PFS2 in ER-positive, HER2-negative advanced breast cancer.
Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.
